Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass

Anesthesia and Analgesia

Volumn 111, Issue 1, 2010, Pages 173-179

  Guzzetta, Nina A ^a   Monitz, Heather G ^b   Fernandez, Janet D ^c   Fazlollah, Tom M ^a   Knezevic, Andrea ^d   Miller, Bruce E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A ANTIBODY; HEPARIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A;

ACTIVATED CLOTTING TIME; ANALYTICAL EQUIPMENT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTIVE SURGERY; FEMALE; HEART SURGERY; HOSPITALIZED INFANT; HUMAN; INFANT; MALE; PEDIATRIC SURGERY; POINT OF CARE TESTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; BLOOD; BLOOD CLOTTING; DOSE RESPONSE; DRUG EFFECT; FALLOT TETRALOGY; HOSPITAL INFORMATION SYSTEM; INSTRUMENTATION; METABOLISM; NEWBORN;

ANTICOAGULANTS; BLOOD COAGULATION; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FEMALE; HEPARIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; POINT-OF-CARE SYSTEMS; TETRALOGY OF FALLOT; WHOLE BLOOD COAGULATION TIME;

EID: 77954663260     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3181e13470     Document Type: Article

References (23)

1. Hirsh J. Mechanism of action and monitoring anticoagulants. Semin Thromb Hemost 1986;12:1-11 vs
2. Bjork I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982;48:161-82
3. Andrew M, MacIntyre B, MacMillan J, Williams WG, Gruenwald C, Johnston M, Burrows F, Wang E, Adams M. Heparin therapy during cardiopulmonary bypass in children requires ongoing quality control. Thromb Haemost 1993;70:937-41
4. Cohen EJ, Camerlengo LJ, Dearing JP. Activated clotting times and cardiopulmonary bypass I: The effect of hemodilution and hypothermia upon activated clotting time. J Extra Corporeal Technol 1980;12:139-41
5. Despotis GJ, Joist JH, Hogue CW Jr, Alsoufiev A, Joiner-Maier D, Santoro SA, Spitznagel E, Weitz JI, Goodnough LT. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996;76:902-8
6. Koster A, Fischer T, Praus M, Haberzettl H, Kuebler WM, Hetzer R, Kuppe H. Hemostatic activation and inflammatory response during cardiopulmonary bypass. Anesthesiology 2002;97:837-41
7. Codispoti M, Ludlam CA, Simpson D, Mankad PS. Individualized heparin and protamine management in infants and children undergoing cardiac operations. Ann Thorac Surg 2001;71:922-8
8. Guzzetta NA, Bajaj T, Fazlollah T, Szlam F, Wilson E, Kaiser A, Tosone SR, Miller BE. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg 2008;106:419-25
9. Yin ET, Wessler S, Butler JV. Plasma heparin: a unique, practical, submicrogram-sensitive assay. J Lab Clin Med 1973;81:298-310
10. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, Cox JL, Lappas DG. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-82
11. Hashimoto K, Sasaki T, Hachiya T, Takakura H, Onoguchi K, Nagahori R, Takeuchi S. Real time measurement of heparin concentration during cardiopulmonary bypass. J Cardiovasc Surg 1999;40:645-51
12. Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1: validation of whole-blood heparin concentration and activated clotting time. Perfusion 2003;18:269-76
13. Gruenwald C, de Souza V, Chan AKC, Andrew M. Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass. Perfusion 2000;15:203-9
14. ® HMS Plus, Hemostasis Management System: Operator's Manual. Minneapolis, MN: Medtronics, Inc., 2002
15. Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery. A review of current and emerging techniques. Anesthesiology 1999;91:1122-51
16. Article: 715878-01C. Kaolin activated clotting time/(kaolinACT). East Windsor, NJ: i-STAT Corporation, 2004
17. Lin LK. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-68
18. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10
19. Kovacs MJ, Keeney M, Mackinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999;21:55-60
20. Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennett M, Horton S, Shann F, Lane G, Ross-Smith M, Monagle P. Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate? Thromb Res 2007;120:347-51
21. Hashimoto K, Yamagishi M, Sasaki T, Nakano M, Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation. Ann Thorac Surg 1994;58:799-804
22. Lemmer JH, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002;123:213-7
23. Avidan MS, Levy JH, van Aken H, Feneck RO, Latimer RD, Ott E, Martin E, Birnbaum DE, Bonfiglio LJ, Kajdasz DK, Despotis GJ. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;130:107-13